FTC pledges to aggressively crack down on pharma mergers
The Federal Trade Commission said Tuesday that it’s setting up an international working group to more closely evaluate pharmaceutical company mergers in light of concerns around drug pricing and anticompetitive behavior.
The FTC, which is now run by Democrats who previously dissented on several prior pharma megamergers, said the working group will consider new mergers in light of pharma companies’ conduct, such as price fixing, reverse payments, and other regulatory abuses. The group will be comprised of state attorneys general, the Department of Justice, as well as UK, European and Canadian regulatory counterparts.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 113,500+ biopharma pros reading Endpoints daily — and it's free.